SaxoTV

Earnings Season: GSK will disappoint but pharma still a healthy sector

380 views
May 06, 2015 bio tech, bio tech stocks, bio technology, biotech, dot com, dot com bubble, dotcom bubble, drugs, drugs sector, earning, earning reports, earnings, earnings 2015, earnings earnings season, earnings expectations, earnings per share, earnings ratio, earnings reports, earnings results, earnings season, earningseason, earningsreports, earningsseason, earningsweek, equities, equities prices, equities trading, equity, equity bubble, equity index, equity market, equity markets, equity platform, equity portfolio, equity portfolios, equity research, equity strategy, equity trading, glaxosmithkline, gsk, health, health care, health industry, health stocks, healthcare, healthcare stocks, novo nordisk, pharma, pharma space, pharmaceutical sales, pharmaceuticals, quarterly outlook, quarterlyoutlook, saxo, saxo bank, saxo bank saxo tv, saxo tv, saxotv, trading, tradingfloor, tradingfloor.com
Expect them to be disappointing. That's what Saxo's Peter Garnry predicts ahead of GlaxoSmithKline publishing its quarterly results. Garnry expects earnings per share to be down around 17% year-on-year.

He's more positive about the healthcare sector as a whole - both biotech and pharma companies as well as those involved in producing healthcare equipment. 

But he says the valuation of the sector is almost at an all-time high, comparing it to the Dotcom bubble. He says this could be an opportunity to short the sector.